The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically
Articolo
Data di Pubblicazione:
2003
Citazione:
The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically / A. Garofalo, E. Naumova, L. Manenti, C. Ghilardi, G. Ghisleni, M. Caniatti, T. Colombo, J.M. Cherrington, E. Scanziani, M. I. Nicoletti, R. Giavazzi. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - 9:9(2003 Aug 15), pp. 3476-3485.
Abstract:
The purpose of this study was to investigate the antitumor activity of SU6668, tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), fibroblast growth factor receptor 1 (FGFR1), and platelet-derived growth factor receptor beta (PDGFRbeta), as single-agent therapy and in combination with paclitaxel on ovarian carcinoma xenograft models transplanted in the peritoneal cavity of nude mice.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Animals ; receptor, platelet-derived growth factor beta ; ovarian neoplasms ; vascular endothelial growth factor receptor-2 ; humans ; protein-tyrosine kinases ; enzyme inhibitors ; mice ; mice, nude ; pyrroles ; receptors, fibroblast growth factor ; cell survival ; neoplasm transplantation ; receptor, fibroblast growth factor, type 1 ; receptor protein-tyrosine kinases ; indoles ; paclitaxel ; antineoplastic combined chemotherapy protocols ; time factors ; female
Elenco autori:
A. Garofalo, E. Naumova, L. Manenti, C. Ghilardi, G. Ghisleni, M. Caniatti, T. Colombo, J.M. Cherrington, E. Scanziani, M. I. Nicoletti, R. Giavazzi
Link alla scheda completa: